FDA approves its first mesenchymal stromal cell therapy
Ryoncil was approved for children with steroid-refractory acute graft-versus-host disease. In the 54-child study, 30% responded completely by day 28.
Day: December 18, 2024
Ryoncil was approved for children with steroid-refractory acute graft-versus-host disease. In the 54-child study, 30% responded completely by day 28.
Access your account activation form, billing and payments, and downloads.
Take the First Step Towards Your Healthier Future!